Did you mean 902 50 0?
Displaying drugs 626 - 650 of 1519 in total
Verzistobart
Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).
Investigational
IKT-001Pro
Investigational
EGEN-001
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
Investigational
Timdarpacept
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Edobacomab
Investigational
BMN-053
Experimental
Withdrawn
Ningetinib
Ningetinib is under investigation in clinical trial NCT03758287 (Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative).
Investigational
BR-007
Investigational
EP-0042
Investigational
VLX-1570
VLX-1570 is under investigation in clinical trial NCT02372240 (A Study of VLX1570 and Dexamethasone in Myeloma Patients).
Investigational
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also...
Investigational
Nix-0699
Investigational
AVR-RD-02
AVR-RD-02 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary...
Investigational
NM-004
Investigational
NX-1207
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Investigational
VY-HTT01
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
BMN-052
Experimental
Withdrawn
Progerinin
Investigational
MK-0668
Experimental
alpha-Hydroxylinoleic acid
alpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).
Investigational
Miransertib
Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
Investigational
MORAb-066
MORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Investigational
Zanzalintinib
Investigational
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Displaying drugs 626 - 650 of 1519 in total